Posted by Michael Wonder on 25 Jun 2025
FDA approves Benlysta (belimumab) auto-injector for children with active lupus nephritis
24 June 2025 - With this approval, paediatric patients aged five years and older with active lupus nephritis will have a first of its kind treatment option for at home administration.
GSK today announced that the US FDA has approved a 200 mg/mL auto-injector of Benlysta (belimumab), a B lymphocyte stimulator specific inhibiting monoclonal antibody, for subcutaneous injection in patients five years of age and older with active lupus nephritis who are receiving standard therapy.
